Sabina Signoretti, MD
Molecular Genetic Pathology · Boston, MANPI 1629510995
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $35,569 of the $36,111 with a category attached, or 98.5%. Astrazeneca UK Limited accounts for 95.0% of it on its own, with 2 other manufacturers making up the rest.
Across 13 payments — averaging $2777.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$34K
- Merck$1K
- E.r. Squibb & Sons, L.L.C.$542
Across 6 payments — averaging $111,056 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Exelixis Inc.$382K
- Merck$269K
- Astrazeneca UK Limited$15K
What the payments were for
- Consulting fees$35,56998%
- Travel & lodging$5171%
- Food & beverage$250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 8 | $34,294 |
| Merck | 1 | $1,275 |
| E.r. Squibb & Sons, L.L.C. | 4 | $542 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few molecular genetic pathology providers in Massachusettsto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other molecular genetic pathology in Boston
- Alanna ChurchBoston$7K
- Harrison TsaiBoston$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.